Oric Pharmaceuticals (ORIC) Income from Continuing Operations (2019 - 2026)
Oric Pharmaceuticals (ORIC) posted Income from Continuing Operations of 140296000.0 for Q1 2026, down 308.07% on a QoQ basis from 34380000.0 in Q4 2025, and down 214.38% year-over-year from 122655930.1 in Q1 2025.
Oric Pharmaceuticals (ORIC) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Oric Pharmaceuticals' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 140296000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 214.38% year-over-year to 140296000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 386652000.0 (up 4.62% YoY) and the FY2025 annual result came in at 355200000.0, down 12.64% from the prior year.
- Income from Continuing Operations was 140296000.0 for Q1 2026 at Oric Pharmaceuticals, down from 34380000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 21817000.0 in Q4 2022 and bottomed at 212475000.0 in Q4 2024.
- A 5-year average of 77401764.71 and a median of 54559000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations slumped 650.63% — and 2025, when it soared 83.82%.
- Oric Pharmaceuticals' Income from Continuing Operations stood at 21817000.0 in 2022, then slumped by 650.63% to 163766000.0 in 2023, then retreated by 29.74% to 212475000.0 in 2024, then surged by 83.82% to 34380000.0 in 2025, then plunged by 308.07% to 140296000.0 in 2026.
- Business Quant data shows ORIC's Income from Continuing Operations at 140296000.0 in Q1 2026, 34380000.0 in Q4 2025, and 116540000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Oric Pharmaceuticals | 1.15 Bn | 866.67 Mn | - | -140.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -140.30 Mn |
| Dec 31, 2025 | -34.38 Mn |
| Sep 30, 2025 | -116.54 Mn |
| Jun 30, 2025 | -95.44 Mn |
| Mar 31, 2025 | -44.63 Mn |
| Dec 31, 2024 | -212.48 Mn |
| Sep 30, 2024 | -89.08 Mn |
| Jun 30, 2024 | -59.21 Mn |
| Mar 31, 2024 | -118.61 Mn |
| Dec 31, 2023 | -163.77 Mn |
| Sep 30, 2023 | -43.70 Mn |
| Jun 30, 2023 | -54.56 Mn |
| Mar 31, 2023 | -37.82 Mn |
| Dec 31, 2022 | -21.82 Mn |
| Sep 30, 2022 | -28.50 Mn |
| Jun 30, 2022 | -25.57 Mn |
| Mar 31, 2022 | -29.44 Mn |
| Dec 31, 2021 | -23.29 Mn |
| Sep 30, 2021 | -66.20 Mn |
| Jun 30, 2021 | -57.13 Mn |